433 related articles for article (PubMed ID: 20958117)
1. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide.
Jensen BO; Selheim F; Døskeland SO; Gear AR; Holmsen H
Blood; 2004 Nov; 104(9):2775-82. PubMed ID: 15265792
[TBL] [Abstract][Full Text] [Related]
3. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies.
Aktas B; Utz A; Hoenig-Liedl P; Walter U; Geiger J
Stroke; 2003 Mar; 34(3):764-9. PubMed ID: 12624305
[TBL] [Abstract][Full Text] [Related]
4. Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein.
Sabetkar M; Naseem KM; Tullett JM; Friebe A; Koesling D; Bruckdorfer KR
Nitric Oxide; 2001 Jun; 5(3):233-42. PubMed ID: 11384196
[TBL] [Abstract][Full Text] [Related]
5. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
6. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
7. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
8. Sodium azide, a bacteriostatic preservative contained in commercially available laboratory reagents, influences the responses of human platelets via the cGMP/PKG/VASP pathway.
Russo I; Del Mese P; Viretto M; Doronzo G; Mattiello L; Trovati M; Anfossi G
Clin Biochem; 2008 Mar; 41(4-5):343-9. PubMed ID: 18022387
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets.
Sudo T; Ito H; Kimura Y
Platelets; 2003 Sep; 14(6):381-90. PubMed ID: 14602552
[TBL] [Abstract][Full Text] [Related]
10. Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.
Kleppe R; Jonassen I; Døskeland SO; Selheim F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462984
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole.
Liu Y; Oh SJ; Chang KH; Kim YG; Lee MY
Biochem Pharmacol; 2013 Oct; 86(7):914-25. PubMed ID: 23876340
[TBL] [Abstract][Full Text] [Related]
12. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans.
Li Z; Ajdic J; Eigenthaler M; Du X
Blood; 2003 Jun; 101(11):4423-9. PubMed ID: 12576312
[TBL] [Abstract][Full Text] [Related]
13. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
Nolte C; Eigenthaler M; Horstrup K; Hönig-Liedl P; Walter U
Biochem Pharmacol; 1994 Oct; 48(8):1569-75. PubMed ID: 7980622
[TBL] [Abstract][Full Text] [Related]
14. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
Azula FJ; Alzola ES; Conde M; Trueba M; Macarulla JM; Marino A
Mol Pharmacol; 1996 Aug; 50(2):367-79. PubMed ID: 8700145
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent inhibitory effects of cGMP-analogues on thrombin-induced platelet-derived microparticles formation, platelet aggregation, and P-selectin expression.
Nygaard G; Herfindal L; Kopperud R; Aragay AM; Holmsen H; Døskeland SO; Kleppe R; Selheim F
Biochem Biophys Res Commun; 2014 Jul; 449(3):357-63. PubMed ID: 24845383
[TBL] [Abstract][Full Text] [Related]
17. cGMP signaling inhibits platelet shape change through regulation of the RhoA-Rho Kinase-MLC phosphatase signaling pathway.
Aburima A; Walladbegi K; Wake JD; Naseem KM
J Thromb Haemost; 2017 Aug; 15(8):1668-1678. PubMed ID: 28509344
[TBL] [Abstract][Full Text] [Related]
18. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.
Mullershausen F; Friebe A; Feil R; Thompson WJ; Hofmann F; Koesling D
J Cell Biol; 2003 Mar; 160(5):719-27. PubMed ID: 12604588
[TBL] [Abstract][Full Text] [Related]
19. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
